Clinical trial · Interventional
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
NCT03898791CI-TRIAL-00053117completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY3295668 Erbumine | Drug | Aurora A Kinase Inhibitor LY3295668 Erbumine | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- LY3295668 Erbumine Cohort A
- description
- LY3295668 erbumine administered orally.
- interventionNames
- Drug: LY3295668 Erbumine
- type
- EXPERIMENTAL
- label
- LY3295668 Erbumine Cohort B
- description
- LY3295668 erbumine administered orally.
- interventionNames
- Drug: LY3295668 Erbumine
- type
- EXPERIMENTAL
- label
- LY3295668 Part JP
- description
- LY3295668 erbumine administered orally.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage. * Have adequate organ function. * Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale. * Have discontinued previous treatments for cancer. * Are able to swallow capsules. Exclusion Criteria: * Currently enrolled in a clinical study. * Have a serious concomitant systemic disorder. * Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C. * Have a significant cardiac condition. * Have previously received an aurora kinase inhibitor.
References
Publications (0)
Data not yet available
No reference posted for this study.